Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors

NCT01975116 is registered in ClinicalTrials.gov with Pediatric Brain Tumor Consortium as lead sponsor.

NCT NCT01975116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01975116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Lead sponsor
Pediatric Brain Tumor Consortium
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
April 30, 2015
Enrollment
18 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligodendroglioma, brainstem tumors, choroid plexus neoplasms, giant cell glioblastoma, glioblastoma, gliosarcoma, medulloblastoma, neuroectodermal tumor, primitive, teratoid tumor, atypical